Millipore Sigma Vibrant Logo

341600 Fibrinogen, Fragment D, Human Plasma

Fibrinogen fragment D is a thermolabile native human plasma protein prepared by digestion of purified fibrinogen followed by preparative electrophoresis.

Fibrinogen, Fragment D, Human Plasma: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
View Products on Sigmaaldrich.com
341600
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
341600-200UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 200 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile core fragment of fibrinogen. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. The D and E fragments have no common antigenic determinants; therefore, no cross-reaction occurs. Reported to increase endothelial membrane permeability to albumin.
      Catalogue Number341600
      Brand Family Calbiochem®
      References
      ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
      Product Information
      FormLyophilized
      FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
      Quality LevelMQ200
      Applications
      ApplicationFibrinogen fragment D is a thermolabile native human plasma protein prepared by digestion of purified fibrinogen followed by preparative electrophoresis.
      Biological Information
      Puritysingle band by SDS-PAGE
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Physicochemical Information
      ContaminantsFragment E: ≤1%
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      341600-200UG 04055977195187

      Documentation

      Fibrinogen, Fragment D, Human Plasma Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Fibrinogen, Fragment D, Human Plasma Certificados de análisis

      CargoNúmero de lote
      341600

      Referencias bibliográficas

      Visión general referencias
      Spraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision24-June-2008 RFH
      DescriptionNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile fragment. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. Fragment D has been shown to increase endothelial monolayer permeability and to decrease polymorphonuclear leukocyte adhesion to endothelial cells. The D and E fragments have no common antigenic determinants; therefore, no cross-reactivity occurs.
      FormLyophilized
      FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Puritysingle band by SDS-PAGE
      ContaminantsFragment E: ≤1%
      SolubilitySterile distilled H₂O (200 µg/ml)
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
      Toxicity Standard Handling
      ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
      Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
      Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
      Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
      Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
      Fisher, E.G., et al. 1991. Haemostasis 21, 141.
      Ge, M., et al. 1991. Am. J. Physiol. 261, L283.